Research graph
References from Meta-analysis of PAX1/JAM3 methylation performance in high-risk HPV-positive women. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
2024 · External reference
2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors.
10.1097/lgt.0000000000000525 · 2020 · External reference
The current position and the future perspectives of cervical cancer screening.
10.1586/14737140.2014.856273 · 2014 · External reference
Molecular markers for cervical cancer screening.
10.1080/14789450.2021.1980387 · 2021 · External reference
Biomarkers for detection of human papillomavirus (HPV).
10.1007/s40944-021-00529-5 · 2021 · External reference
Cancer epigenetics in clinical practice.
2023 · External reference
Feasibility evaluation of using PAX1/JAM3 methylation markers as cervical cancer screening for female self‑collected samples.
2024 · External reference
High-grade cervical lesions diagnosed by JAM3/PAX1 methylation in high-risk human papillomavirus-infected patients.
2023 · External reference
The performance of JAM3/PAX1 methylation in the diagnosis of high-grade squamous intraepithelial lesions for women with high-risk HPV infection.
10.1186/s12885-024-13299-y · 2024 · External reference
Assessment of PAX1 and JAM3 methylation triage efficacy across HPV genotypes and age groups in high-risk HPV-positive women in China.
10.3389/fonc.2024.1481626 · 2024 · External reference
Triage performance of DNA methylation for women with high-risk human papillomavirus infection.
10.1093/oncolo/oyae324 · 2025 · External reference
Cervical cancer screening: efficacy of PAX1 and JAM3 methylation assay in the triage of atypical squamous cell of undetermined significance (ASC-US).
10.1186/s12885-024-13082-z · 2024 · External reference
A multicenter study on the accuracy of PAX1/JAM3 dual genes methylation testing for screening cervical cancer.
2024 · External reference
The triage role of cytological DNA methylation in women with non-16/18, specifically genotyping high-risk HPV infection.
10.1038/s41416-025-03005-5 · 2025 · External reference
Triage performance of PAX1(m)/JAM3(m) in opportunistic cervical cancer screening of non‒16/18 human papillomavirus-positive women: a multicenter prospective study in China.
10.1186/s13148-024-01731-w · 2024 · External reference
Evaluating PAX1/JAM3 methylation for triage in HPV 16/18-infected women.
10.1186/s13148-024-01804-w · 2024 · External reference
Cytologic DNA methylation for managing minimally abnormal cervical cancer screening results.
10.1002/ijgo.70167 · 2025 · External reference
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections.
10.1093/jnci/djn044 · 2008 · External reference
The role of DNA methylation and DNA methyltransferases in cancer.
10.1007/978-3-031-11454-0_13 · 2022 · External reference
An epigenomic landscape of cervical intraepithelial neoplasia and cervical cancer using single-base resolution methylome and hydroxymethylome.
10.1002/ctm2.498 · 2021 · External reference
An 8-gene DNA methylation signature predicts the recurrence risk of cervical cancer.
10.1177/03000605211018443 · 2021 · External reference
A prospective study on the predictive value of DNA methylation in cervical intraepithelial neoplasia prognosis.
10.1007/s00404-018-4796-3 · 2018 · External reference
Value of PAX1 methylation analysis by MS-HRM in the triage of atypical squamous cells of undetermined significance.
10.7314/apjcp.2015.16.14.5843 · 2015 · External reference
JAM3 methylation status as a biomarker for diagnosis of preneoplastic and neoplastic lesions of the cervix.
10.18632/oncotarget.6250 · 2015 · External reference
2022-RA-902-ESGO 2005; Novel methylated genes as a second triage step after hrHPV testing to improve colposcopy referral in HPV infected women with cervical lesions (cancer).
10.1136/ijgc-2022-esgo.875 · 2022 · External reference
An epigenomic landscape of cervical intraepithelial neoplasia and cervical cancer using single-base resolution methylome and hydroxymethylome.
10.1002/ctm2.498 · ExternalCitation · doi-reference
Cytologic DNA methylation for managing minimally abnormal cervical cancer screening results.
10.1002/ijgo.70167 · ExternalCitation · doi-reference
The role of DNA methylation and DNA methyltransferases in cancer.
10.1007/978-3-031-11454-0_13 · ExternalCitation · doi-reference
A prospective study on the predictive value of DNA methylation in cervical intraepithelial neoplasia prognosis.
10.1007/s00404-018-4796-3 · ExternalCitation · doi-reference
Biomarkers for detection of human papillomavirus (HPV).
10.1007/s40944-021-00529-5 · ExternalCitation · doi-reference
The triage role of cytological DNA methylation in women with non-16/18, specifically genotyping high-risk HPV infection.
10.1038/s41416-025-03005-5 · ExternalCitation · doi-reference
Molecular markers for cervical cancer screening.
10.1080/14789450.2021.1980387 · ExternalCitation · doi-reference
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections.
10.1093/jnci/djn044 · ExternalCitation · doi-reference
Triage performance of DNA methylation for women with high-risk human papillomavirus infection.
10.1093/oncolo/oyae324 · ExternalCitation · doi-reference
2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors.
10.1097/lgt.0000000000000525 · ExternalCitation · doi-reference
2022-RA-902-ESGO 2005; Novel methylated genes as a second triage step after hrHPV testing to improve colposcopy referral in HPV infected women with cervical lesions (cancer).
10.1136/ijgc-2022-esgo.875 · ExternalCitation · doi-reference
An 8-gene DNA methylation signature predicts the recurrence risk of cervical cancer.
10.1177/03000605211018443 · ExternalCitation · doi-reference
Cervical cancer screening: efficacy of PAX1 and JAM3 methylation assay in the triage of atypical squamous cell of undetermined significance (ASC-US).
10.1186/s12885-024-13082-z · ExternalCitation · doi-reference
The performance of JAM3/PAX1 methylation in the diagnosis of high-grade squamous intraepithelial lesions for women with high-risk HPV infection.
10.1186/s12885-024-13299-y · ExternalCitation · doi-reference
Triage performance of PAX1(m)/JAM3(m) in opportunistic cervical cancer screening of non‒16/18 human papillomavirus-positive women: a multicenter prospective study in China.
10.1186/s13148-024-01731-w · ExternalCitation · doi-reference
Evaluating PAX1/JAM3 methylation for triage in HPV 16/18-infected women.
10.1186/s13148-024-01804-w · ExternalCitation · doi-reference
The current position and the future perspectives of cervical cancer screening.
10.1586/14737140.2014.856273 · ExternalCitation · doi-reference
JAM3 methylation status as a biomarker for diagnosis of preneoplastic and neoplastic lesions of the cervix.
10.18632/oncotarget.6250 · ExternalCitation · doi-reference
Assessment of PAX1 and JAM3 methylation triage efficacy across HPV genotypes and age groups in high-risk HPV-positive women in China.
10.3389/fonc.2024.1481626 · ExternalCitation · doi-reference
Value of PAX1 methylation analysis by MS-HRM in the triage of atypical squamous cells of undetermined significance.
10.7314/apjcp.2015.16.14.5843 · ExternalCitation · doi-reference
